The Methylation Game: Epigenetic and Epitranscriptomic Dynamics of 5-Methylcytosine

Adele Alagia and Monika Gullerova *

Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom

DNA and RNA methylation dynamics have been linked to a variety of cellular processes such as development, differentiation, and the maintenance of genome integrity. The correct deposition and removal of methylated cytosine and its oxidized analogues is pivotal for cellular homeostasis, rapid responses to exogenous stimuli, and regulated gene expression. Uncoordinated expression of DNA/RNA methyltransferases and demethylase enzymes has been linked to genome instability and consequently to cancer progression. Furthermore, accumulating evidence indicates that post-transcriptional DNA/RNA modifications are important features in DNA/RNA function, regulating the timely recruitment of modification-specific reader proteins. Understanding the biological processes that lead to tumorigenesis or somatic reprogramming has attracted a lot of attention from the scientific community. This work has revealed extensive crosstalk between epigenetic and epitranscriptomic pathways, adding a new layer of complexity to our understanding of cellular programming and responses to environmental cues. One of the key modifications, m^5C, has been identified as a contributor to regulation of the DNA damage response (DDR). However, the various mechanisms of dynamic m^5C deposition and removal, and the role m^5C plays within the cell, remains to be fully understood.

Keywords: DNA, RNA, m^5C, hm^5C, methyltransferases, demethylases, cancer, DNA damage

INTRODUCTION

Gene expression regulation is not only affected by mutations in the genomic sequence, but also by various other molecular mechanisms (Allis and Jenuwein, 2016), such as epigenetic regulation. Epigenetic regulation can influence gene expression profiles regardless of the genomic sequence, and can result in either the condensation or relaxation of the chromatin structure (Dai et al., 2020). The main players in epigenetic control; m^3C DNA methylation, histone modifications, and non-coding RNAs (Kumar et al., 2018), have been linked to genome stability and are known to contribute to the maintenance of genome integrity (Deem et al., 2012). Three distinct aspects govern epigenetic status; inheritance, environmental factors, and stability over time (Bonasio et al., 2010). Epigenetic modifications are stable enough to maintain cellular homeostasis, but are also reversible to allow transitions among different states and responses to environmental cues (Zhang et al., 2019). The dynamic nature of epigenetic features controls several aspects of transcription regulation and consequently influences many physiological processes, such as development (John and Rougeulle, 2018), transposon control (Msiak et al., 2019), and brain and memory formation (Kim and Kaang, 2017). Furthermore, deregulation of epigenetic processes can lead to genomic instability, promoting the onset and development of different diseases including cancer (Lu et al.,...
2020) (Liu et al., 2017). For example, during cancer development, genome-wide DNA hypomethylation and genespecific hypermethylation occur as a consequence of mutated or deregulated chromatin modifiers (Ibrahim et al., 2022). Thus, epigenetic alterations or epimutations (McCarrey et al., 2016) result in abnormal transcriptional repression or activation of genes (Lee, 2019). Epimutations can be classified into two groups: primary, which are epigenetic alterations in the absence of a genetic change, and secondary epimutations, which are acquired as a consequence of DNA mutations in genes of cis or trans-acting chromatin factors (Oey and Whitelaw, 2014). Interestingly, secondary epimutations are the most reported in cancers (Ruiz de la Cruz et al., 2021). At a molecular level, epigenetics involves a complex and dynamically reversible set of structural modifications of chromatin catalysed by enzymes often referred to as “writers,” which add different chemical modifications such as methyl group moieties to DNA (Biswas and Rao, 2018). These molecular decorations are then able to recruit a plethora of proteins called “readers” that specifically recognize these moieties (Du et al., 2015). Finally, a set of “erasers” catalyzes the removal of the deposited modification. Writers, readers, and erasers function dynamically to regulate the epigenetic landscape. Concerted variations of epigenetic modifications ensure an organism’s normal development and its responsiveness to environmental stimuli (Norouzitallab et al., 2019). Removal and restoration of methylation marks is also important during embryonic development, with coordinated waves of demethylation and de novo methylation establishing specific cell fates (Wu and Zhang, 2014). With recent advances in high-throughput sequencing techniques and transcriptome-wide studies, more than 150 post-transcriptional modifications have been also described on RNA, termed the epitranscriptome (Ma et al., 2022). Similarly to DNA methylation, RNA bases can be methylated and can function in the fine-tuning of gene expression (Kumar and Mohapatra, 2021) (Seo and Kleiner, 2021) (Willbanks et al., 2021). Eptitranscriptomic studies have also revealed how post-transcriptional RNA modifications can dynamically affect several aspects of RNA metabolism including processing, export, translation, and RNA stability (Flamand and Meyer, 2019; Ranjan and Leidel, 2019; Trixl and Lusser, 2019; Zhao et al., 2020). Although the m^5C modification on RNA has been demonstrated to play a role in the pathogenesis of several diseases, the mechanism of action remains largely unexplored. Furthermore, evidence of changes in the transcriptional landscape driven by m^5C during several physiopathological processes, ranging from pluripotency, development, differentiation, genome instability, and oncogenesis has been reported (Frye et al., 2018; Bohnsack et al., 2019; He et al., 2020; Song et al., 2022). A large amount of scientific literature describes cancer as a genetic, epigenetic, and epitranscriptomic disease (Esteller and Pandolfi, 2017; Lobos et al., 2018; Porcellini et al., 2018; Xue et al., 2020a; Esteve-Puig et al., 2020; Xie et al., 2020; Miano et al., 2021; Lopez et al., 2022). Oncogenesis driven by genome instability and consequentially accumulation of mutations is a complex pathological process that involves changes in gene expression. Both hypermethylation and hypomethylation at different genetic loci and of RNAs is strongly correlated to tumour initiation, progression, and metastasis (Pérez et al., 2018; Locke et al., 2019; Nishiyama and Nakanishi, 2021). Furthermore, deregulated deposition and removal of methylation marks as a result of deregulated writer and eraser enzymes has also been described as a hallmark of cancer chemotherapy resistance (Ginno et al., 2020; Romero-Garcia et al., 2020; Feng et al., 2021a; Sun et al., 2021a; Zhao et al., 2021). In this review, we summarise the current insights surrounding the dynamics of m^5C and its oxidized derivatives (hm^5C, f^5C, and ca^5C) and their relevance in pathophysiological contexts such as pluripotency, development, differentiation, the DNA damage response, and cancer.

**DNA/RNA CYTOSINE METHYLATION**

The addition of a methyl group at the carbon-5 position of cytosine in DNA in the CpG dinucleotide context is catalysed by the S-adenosyl-methionine-dependent DNMT methyltransferase family. DNMT1 primarily maintains DNA methylation patterns during replication, while DNMT3A, DNMT3B, and DNMT3L are involved in transcriptional regulation. In contrast, RNA methylation is largely catalysed by the TET (Ten-1, mC-5ε, TpG) enzymes, which oxidize cytosines to 5-hydroxymethylcytosine (5hmC) derivatives (hm^5C, f^5C, and ca^5C). These modifications play a role in the regulation of gene expression by altering the transcriptional landscape.
DNMT3B, and DNMT3L are predominantly involved in the establishment of de novo DNA methylation (Figure 1) (Lyko, 2018). Proper maintenance of DNA methylation patterns defines the structural and functional identities of cells throughout cell division (Moore et al., 2013). Although DNA methylation patterns are stable, active and passive demethylation modulates a dynamic methylation process (Sadakierska-Chudy et al., 2015). Passive demethylation or replication-dependent dilution occurs after the synthesis of newly replicated DNA strands. Without functional DNA m^5C methylation maintenance of newly synthesized DNA strands, the symmetry of methylation is not re-established and methylation is lost through replication cycles. On the other hand, DNA methylation can be actively reversed by family of α-ketoglutarate-dependent dioxygenases, known as Ten-eleven Translocation (TET) proteins, which exist as 3 isoforms: TET1, TET2, TET3 (Lan et al., 2020). Hydroxylation of m^5C analogue to 5-Hydroxymethylcytosine (hm^5C), 5-formylcytosine (f^5C) and 5-carboxylcytosine (ca^5C). This glycosylase activity of TDG allows the excision of Tet-produced f^5C or ca^5C nucleobases. Created with BioRender.com.

DNMT3B, and DNMT3L are predominantly involved in the establishment of de novo DNA methylation (Figure 1) (Lyko, 2018). Proper maintenance of DNA methylation patterns defines the structural and functional identities of cells throughout cell division (Moore et al., 2013). Although DNA methylation patterns are stable, active and passive demethylation modulates a dynamic methylation process (Sadakierska-Chudy et al., 2015). Passive demethylation or replication-dependent dilution occurs after the synthesis of newly replicated DNA strands. Without functional DNA m^5C methylation maintenance of newly synthesized DNA strands, the symmetry of methylation is not re-established and methylation is lost through replication cycles. On the other hand, DNA methylation can be actively reversed by family of α-ketoglutarate-dependent dioxygenases, known as Ten-eleven Translocation (TET) proteins, which exist as 3 isoforms: TET1, TET2, TET3 (Lan et al., 2020). Hydroxylation of m^5C analogue to 5-Hydroxymethylcytosine (hm^5C), 5-formylcytosine (f^5C) and 5-carboxylcytosine (ca^5C). This glycosylase activity of TDG allows the excision of Tet-produced f^5C or ca^5C nucleobases. Created with BioRender.com.

Changes in the m^5C deposition pattern in mRNA is also associated with several hallmarks of cancer including cell survival, proliferation, invasion, and resistance to therapy (Schumann et al., 2020; Huang et al., 2019). Furthermore, the majority of m^5C patterns on RNA are lineage- and tissue-specific (Amort et al., 2017). The presence of the m^5C modification has been described on both the small and large rRNA subunits. M^5C controls ribosome synthesis and processing, and can alter the conformation of the rRNA, effecting translation fidelity (Schosserer et al., 2015; Popis et al., 2016). In tRNA, m^5C is mostly present at the junction of the variable loop and the T-stem spanning positions (47-50) (Van Haute et al., 2019). The presence of m^5C on tRNA has been linked to proper folding of the tRNA molecule into an L-shaped structure. However, m^5C has been also shown to be present at the C38 position in the anticodon loop of tRNA and can modulate the translation fidelity of a specific subset of genes (Huang et al., 2021a). In mRNA, m^5C modification is enriched in 5’/3’-UTRs, next to Argonaute-binding regions, but is depleted in coding regions (Figure 2). m^5C has been also detected in many ncRNAs such as lncRNAs, lincRNAs, pseudogene transcripts, antisense transcripts, and vault RNAs (Amort et al., 2013; Khoddami and Cairns, 2013; Sajini et al., 2019; Sun et al., 2020), and its presence is likely to be linked to processing, stability, and interaction with m^5C reader proteins.
5-METHYLCYTOSINE MODIFICATION IN CANCER ONSET

m^5C-driven epigenetic and epitranscriptomic events are entwined in cellular homeostasis. Deregulated m^5C deposition can promote cancer development as a consequence of deregulation of both DNA and RNA molecules (Sun et al., 2021b). The m^5C-mediated upregulation of proto-oncogenes or silencing of tumour suppressor genes, together with an enhanced translation rate and stability of mRNA oncogenes, are common molecular events in many types of cancers including leukaemia, breast, bladder, gastric, ovarian, colorectal, and lung (Atala, 2020; Zhang et al., 2020a; Sun et al., 2020; Hu et al., 2021a; Huang et al., 2021b; Li et al., 2021b). Furthermore, alterations in DNMTs expression levels or activity have been linked to both hypermethylation of tumour-suppressor genes and hypomethylation of proto-oncogene genes (Nishiyama and Nakanishi, 2021). In addition, overexpression of the RNA m^5C writer NSUN2 (Okamoto et al., 2012; Yi et al., 2017; Cheng et al., 2018; Chellamuthu and Gray, 2020; Xiang et al., 2020; Hu et al., 2021a; Su et al., 2021; Wang et al., 2022) and RNA m^5C reader YBX1, has been associated with mRNA hypermethylation and oncogene activation (Chen et al., 2019). Furthermore, the NSUN2-YBX1-oncogene axis is a commonly deregulated pathway during the cancer onset and progression (Wang et al., 2022).

TEN-ELEVEN TRANSLOCATION-DRIVEN ITERATIVE 5-METHYLCYTOSINE OXIDATION (5-HYDROXYMETHYLCYTOSINE > 5-FORMYLCYTOSINE > 5-CARBOXYLCYTOSINE) IN DNA AND RNA

The presence of m^5C in the genome is dynamically controlled by the antagonising action of specific writers and erasers. DNMT family members are mainly responsible for the deposition of m^5C at both the DNA and RNA level, while Ten-eleven translocation (TET) proteins are considered m^5C erasers. Active demethylation of m^5C is achieved by TET-mediated sequential oxidation with the production of hm^5C (5-Hydroxymethylcytosine), f^5C (5-formylcytosine), ca^5C (5-carboxylcytosine) analogues (Figure 1) (Ito et al., 2011). Then, the N-glycosidic bond of f^5C and ca^5C is processed by the Thymine DNA Glycosylase (TDG) to form abasic sites, DNA damage repair (Ketley and Gullerova, 2020), a pioneering study has investigated the possibility of RNA post-transcriptional modification relevance in DNA double strand break (DSB) repair. DNMT2/TRDMT1 protein was shown to be recruited to damage sites, where it is able to catalyse the deposition of m^5C residues onto DNA:RNA hybrids (Chen et al., 2020a). m^5C-modified DNA:RNA hybrids promoted the recruitment of specific readers including Rad52, which drives the later stages of DNA repair. In addition, loss of DNMT2 proved to be detrimental during the DNA damage response, suggesting the importance of m^5C presence during HR-mediated DNA damage repair (Zhu et al., 2021).

5-METHYLCYTOSINE MODIFICATION IN DNA DAMAGE RESPONSE

Since several RNA species (DNA damage response RNAs, damage-induced IncRNAs, de novo transcripts and DNA:RNA hybrids) have been described to be essential during DNA damage repair (Ketley and Gullerova, 2020), a pioneering study has investigated the possibility of RNA post-transcriptional modification relevance in DNA double strand break (DSB) repair. DNMT2/TRDMT1 protein was shown to be recruited to damage sites, where it is able to catalyse the deposition of m^5C residues onto DNA:RNA hybrids (Chen et al., 2020a). m^5C-modified DNA:RNA hybrids promoted the recruitment of specific readers including Rad52, which drives the later stages of DNA repair. In addition, loss of DNMT2 proved to be detrimental during the DNA damage response, suggesting the importance of m^5C presence during HR-mediated DNA damage repair (Zhu et al., 2021).
followed by Base Excision Repair (BER) to restore the unmodified cytosine (He et al., 2011; Bordin et al., 2021). Alternative pathways include; 1) direct deformylation (f5C) and decarboxylation (ca5C) mediated by DNMT3A/B (Feng et al., 2021b), 2) AID/APOBEC-dependent deamination and production of 5hmU followed by TDG cleavage (Cervantes-Gracia et al., 2021), and 3) passive DNA replication-dependent loss (Vincenzetti et al., 2019). However, TET enzymes appeared to be involved in the oxidation of both DNA and RNA m5C (Wu and Zhang, 2011; Fu et al., 2014; He et al., 2021a). In vitro studies confirmed that double stranded DNA is the preferred TET substrate, followed by DNA:RNA hybrids, single stranded DNA and single stranded RNA. Double strand RNA molecules were shown not to be TET substrates, likely due to TET discrimination against the RNA A-form conformation (DeNizio et al., 2019).

5-HYDROXYMETHYLCYTOSINE

The hm5C mark has been annotated at promoters, enhancers, and in gene bodies (Cui et al., 2020). While hm5C is mainly associated with active gene transcription and an open chromatin structure, its role depends on the genomic context (active vs. poised genes) (Choi et al., 2014). Furthermore, hm5C modification has a locus and tissue specific signature and serves as a feature of cellular state and identity. Genome-wide mapping at a single-nucleotide resolution level using modification specific antibodies, has estimated that around the 5% of cytosine residues in mammalian genome are modified as m5C and less than the 1% are hm5C (He et al., 2021b). The presence hm5C has been described not only at promoters, enhancers and gene body regions, but also on several RNA molecules (Delatte et al., 2016). m5C and hm5C modifications have been identified as stable epigenetic marks, and different chromatin-binding proteins have been shown to specifically bind to either m5C or hm5C, suggesting these modifications have distinct functions in epigenetic regulation. Recent studies have identified several proteins which preferentially “read” m5C or its oxidized forms. For example, the Methyl-CpG binding domain (MBD) protein family plays a pivotal role in determining the transcriptional state of the epigenome and shows a strong preference for hm5C over the m5C modification (Buchmuller et al., 2020). MBD proteins mainly belong to chromatin-bound repressor complexes, which coordinate crosstalk between m5C methylation, histone modifications, and chromatin organization. TET-mediated hm5C biogenesis blocks the reader function of the MBDS and alleviates their transcriptional repression, producing a new platform for hm5C specific readers and transcriptional activation.

5-FORMYLCYTOSINE AND 5-CARBOXYLCYTOSINE

Despite the fact that f5C and ca5C oxidized forms of m5C are considered short-lived intermediates in the demethylation process, and their steady-state levels are many orders of magnitude lower than hm5C, emerging evidence indicates that f5C and ca5C might have independent epigenetic signalling roles in recruiting modification-specific “reader” proteins (Song and He, 2013). f5C and ca5C can be recognized by transcriptional regulators, DNA repair factors, and chromatin regulators, predominantly stimulating gene activation. Beside these regulatory roles, some studies have proposed the TET-mediated oxidative products f5C and ca5C are mutagenic bases that can threaten the genomic integrity if not properly eliminated. Moreover, deregulation of TET-TDG-BER pathway and inefficient f5C and ca5C clearance has been linked to DNA damage and the production of DSBs (Weber et al., 2016).

5-HYDROXYMETHYLCYTOSINE MODIFICATION IN PLURIPOTENCY, DEVELOPMENT, AND DIFFERENTIATION

Transcriptome flexibility is required for embryonic stem cell (ESC) differentiation (Dawlaty et al., 2014; Lan et al., 2020). Cell fate commitment requires efficient and timely control of the expression of pluripotency-associated factors. hm5C can promote a rapid response during differentiation processes (Cimmino et al., 2011; Kuehner et al., 2021). The RNA hm5C modification has been described as a guardian of the transcriptional landscape, able to regulate the balance between pluripotency and lineage-priming mRNAs and ensures ESC differentiation in a timely and orderly manner (Wu et al., 2018; Yang et al., 2020). TET-dependent hydroxymethylation of mRNA molecules can regulate RNA half-life and splicing. In mouse embryonic stem cells (mESCs) hm5C has been linked to the downregulation of certain mRNAs linked to pluripotency allowing ESC-to-EB (embryo body) differentiation (Lan et al., 2020). During somatic reprogramming to pluripotency, hm5C deposition drives site-specific demethylation of reprogramming enhancers and promoters resulting in the formation of iPSC (induced pluripotent stem cells) (Caldwell et al., 2021). TET triple knockout cells failed to undergo iPSC reprogramming, highlighting the importance of m5C hydroxylation during state transitions. Furthermore, a report on somatic reprogramming determined the contribution of hm5C deposition decoupled from the production of the oxidative derivatives f5C and ca5C using a hm5C-stalled TET enzyme. Interestingly, hm5C deposition alone is not sufficient for iPSC reprogramming, and f5C, ca5C and the TDG protein appeared to be crucial in this process, suggesting a different role of hm5C and the f5C and ca5C epigenetic signatures (Caldwell et al., 2021).

5-HYDROXYMETHYLCYTOSINE MODIFICATION IN CANCER ONSET

hm5C has been proposed to act as a novel diagnostic and prognostic marker in several human malignancies (Scurouzic et al., 2015; An et al., 2017). Loss or inactivation of TET
enzymes and deregulation of m⁵C demethylation are emerging as crucial determinants for cancer phenotypes. Modulation of the expression and activity of TET proteins can occur as a result of different mechanisms, such as m⁶C-mediated silencing of the TET loci or changes in the intracellular concentration of TET co-factors (i.e., α-Ketoglutarate, oxygen, iron, vitamin C) (Scourzic et al., 2015; Yue and Rao, 2020; Matulevicute et al., 2021). Several studies have outlined a negative correlation between the loss of TET activity with increased levels of m⁶C and decreased levels of hm⁵C, and poor prognosis in cancers including lung, cervical, breast, glioblastoma, and hematopoietic (López-Moyado et al., 2019; Gao et al., 2021; Xu et al., 2021; Lopez-Bertoni et al., 2022; Xu et al., 2022). The deregulation of m⁶C and hm⁵C affects cell transcriptional programs and leads to cancer stem-like phenotypes. Moreover, aberrant deposition of hm⁵C has been also proposed as a contributing factor to chemotherapy resistance (Kharat and Sharan, 2020).

5-HYDROXYMETHYLCYTOSINE MODIFICATION IN THE DNA DAMAGE RESPONSE

Of note, TET-mediated hm⁵C accumulation has also been described at DNA damage, suggesting a crucial role for hm⁵C in promoting DNA damage repair (Kafar et al., 2016). Possible mechanisms of action could be linked to the ability of hm⁵C to promote or maintain an open chromatin configuration. hm⁵C modification is able to control DNA accessibility through a DNA-end breathing motion that can decrease nucleosome affinities, facilitate RNA polymerase II elongation, and lower the thermodynamic stability of the DNA duplex (Mendonca et al., 2014; Li et al., 2022). Local accessibility of hm⁵C chromatin driven by hm⁵C, could serve as a platform for the recruitment of late-acting DNA damage repair factors. The hm⁵C modification has also been found to promote the formation of DNA:RNA hybrids (R-loops) in vitro and in vivo (Sabino et al., 2022; Shukla et al., 2022; Yang et al., 2022). Given that DNA:RNA hybrids are well-established triggers of DNA damage, hm⁵C modification has been proposed as novel player in genome instability. Several studies have documented a direct association between TET deficiency and increased level of DNA double strand breaks caused by the accumulation of R-loop structures. Ineffective m⁵C demethylation can further impair DNA damage repair through the retention of m⁵C readers on the R-loops and delayed R-loop resolution. Even if hm⁵C deposition in DNA damage responses is not fully understood, a direct correlation between the level of hm⁵C and fork stability has recently been described (Kharat et al., 2020). Upon DNA damage, ATM and ATR kinases can phosphorylate TET proteins and stimulate hm⁵C deposition close to the replication fork. The excessive presence of hm⁵C at replication forks triggers BER-mediated repair of hm⁵C, leading to the production of abasic sites which could sources of genome instability.

BEYOND 5-METHYLCYTOSINE: THE ROLE OF N6-METHYLATED ADENOSINE MODIFICATION

Dynamic and reversible chemical control of DNA and RNA also encompasses other methylated nucleobases. So far, several enzymatically methylated residues including N6-methyladenosine (m⁶A) (Zhu et al., 2020), N1-methyladenosine (m⁶A) (Xiong et al., 2018), N7-methylguanosine (m⁷G) (Eiroth et al., 2019) and N4-methylcytosine (m⁴C) (Chen et al., 2020b) have been described in all major RNA types, while their presence in DNA is mainly restricted to m⁶A (Xu and Bochtler, 2020). For example, the existence of m⁶A in DNA has been suggested to be dependent on RNA catabolism rather than a specific m⁶A writer, arguing against the proposed role of m⁶A as a heritable epigenetic mark (Musheev et al., 2020). This evidence is also corroborated by the homogeneous distribution of m⁶A throughout the genome, implying an incorporation of m⁶A form the RNA nucleoside pool rather than from the direct action of a DNA methyltransferase. Although some reports have proposed a role for m⁶A in the epigenetic control of the heterochromatin formation, m⁶A-mediated regulation of chromatin dynamics appears to depend more on m⁶A methylated RNAs such as chromosome-associated regulatory RNAs (carRNAs) (Zhang et al., 2020b; Liu et al., 2020; Selmi and Lanzuolo, 2022) rather than a direct effect of m⁶A deposition in the genome. Nevertheless, m⁶A is a well-established RNA epitranscriptomic mark and its dynamical and reversible write and erase processes are mainly regulated by some members of the methyltransferase-like gene family (METTL1, METTL13 and METTL14) and FTO and ALKBH5 enzymes, respectively (Meyer and Jaffrey, 2014). The m⁶A writing process predominantly occurs in the nucleus, while reading and erasing events are reported in both the nucleus and cytoplasm. Distinctive subcellular localization of m⁶A erasers and readers confers the specific roles of the m⁶A residue, and thereby influences different pathways. m⁶A functions have been linked to several biological processes such as modulation of splicing by altering the structure of pre-mRNAs (Zhou et al., 2019), increased miRNA biogenesis by enhancing the recognition and processing of the microRNA microprocessor complex protein DGR8 (Han et al., 2021), transcription termination by facilitating the co-transcriptional R-loops formation (Yang et al., 2019), regulation of DNA damage repair by the accumulation of DNA:RNA hybrids at DSB sites (Zhang et al., 2020c; Qu et al., 2021) development and pluripotency (Zhang et al., 2020b; Jin et al., 2021). Furthermore, it has been reported that m⁶A modification can influence mRNA export from the nucleus, determine transcripts turnover and stimulate translation initiation (Jiang et al., 2021). Perturbation of m⁶A deposition and elimination dynamics, due to upregulated or mutated enzymes, has been associated with tumor initiation and progression, metastasis, cell proliferation and self-renewal (He et al., 2019; Zhou et al., 2020). Moreover, opposite effects of m⁶A modification levels reported in some cancer settings (e.g., ovarian cancers), can be explained by the involvement of specific m⁶A readers in the stability of either oncogene or tumor-suppressor m⁶A-modified mRNAs (Chen et al., 2021b; Huang et al., 2022).
CONCLUDING REMARKS

A growing body of evidence suggest that epigenetic and epitranscriptomic dynamics are profoundly interconnected. Methyltransferases ("writers") and demethylases ("erasers") functionally cooperate and compete to maintain the appropriate amount of m5C and its oxidized derivatives across both the genome and the transcriptome. Maintenance of effective, time regulated, and lineage-specific methylation-demethylation dynamics is needed for cellular homeostasis and responses to diverse stimuli. Mutations in epigenetic and epitranscriptomic modifiers can deregulate normal cellular differentiation and programmed growth control. As a consequence of altered patterns of hm5C and m5C, mainly characterised by global hypomethylation and focal hypermethylation, multiple stages of tumorigenesis including initiation, progression and metastasis, are promoted. Moreover, numerous reports correlate the loss of hm5C with poor prognosis. Restoration of proper methylation-demethylation dynamics in cells could be achieve with several approaches. Identification of druggable targets of both main players (DNMTs, TETs) and pivotal intermediates (miRNAs or lncRNAs) is crucial for the development of classical inhibitors or RNA-based drugs. A combination of epigenetic therapy and classical chemotherapy is a promising approach aiming at reducing tumour growth and self-renewal characteristics, while reducing chemoresistance (Hu et al., 2021b).

In addition, the intriguing possibility of precise and synchronized crosstalks between diverse epigenetic and epitranscriptomic marks (e.g., m5C and m6A) (Rengaraj et al., 2021) as versatile checkpoints in the maintenance of cellular homeostasis, may underpin a complex and comprehensive landscape of the cellular methylation game.

AUTHOR CONTRIBUTIONS

AA and MG discussed the structure and content of the review. AA wrote the draft and MG edited the draft.

FUNDING

This work was supported by the Senior Research Fellowship by Cancer Research United Kingdom (grant number BVR01170) awarded to MG, EPA Trust Fund (BVR01670) awarded to MG and Lee Placito Fund awarded to MG.

ACKNOWLEDGMENTS

We are grateful to all members of MG lab, in particular to R.F. Kety for her help with this manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2022.915685/full#supplementary-material

REFERENCES

Allis, C. D., and Jenuwein, T. (2016). The Molecular Hallmarks of Epigenetic Control. Nat. Rev. Genet. 17, 487–500. doi:10.1038/nrg.2016.59
Amort, T., Soulière, M. F., Wille, A., Jia, X. Y., Figel, H., Wörle, H., et al. (2013). Long Non-coding RNAs as Targets for Cytosine Methylation. RNA Biol. 10, 1003–1008. doi:10.4161/rna.24454
Amort, T., Rieder, D., Wille, A., Khokhlova-Cubberley, D., Rüm, C., Trixl, L., et al. (2017). Distinct 5-methylcytosine Profiles in Poly(A) RNA from Mouse Embryonic Stem Cells and Brain. Genome Biol. 18, 1. doi:10.1186/s13059-016-1139-1
An, J., Rao, A., and Ko, M. (2017). TET Family Dioxgenases and DNA Demethylation in Stem Cells and Cancers. Exp. Mol. Med. 49, e323. doi:10.1038/emmm.2017.5
Atala, A. (2020). Re: 5-Methylcytosine Promotes Pathogenesis of Bladder Cancer through Stabilizing mRNAs. J. Urology 203, 884–885. doi:10.1097/ju.0000000000008781
Awah, C. U., Winter, J., Mazdooq, C. M., and Ogunwobi, O. O. (2021). NSUN6, an RNA Methyltransferase of 5-mC Controls Glioblastoma Response to Temozolomide (TMZ) via NELFB and RPS6KB2 Interaction. Cancer Biol. Ther. 22, 587–597. doi:10.1080/15384047.2021.1990631
Biswas, S., and Rao, C. M. (2018). Epigenetic Tools (The Writers, The Readers and The Erasers) and Their Implications in Cancer Therapy. Eur J. Pharmacol. 837, 8–24. doi:10.1016/j.ejphar.2018.08.021
Bohnscack, K. E., Höbartner, C., and Bohnscack, M. T. (2019). Eukaryotic 5-methylcytosine (m5C) RNA Methyltransferases: Mechanisms, Cellular Functions, and Links to Disease. Genes (Basel) 10, 102. doi:10.3390/genes10020102
Bonasio, R., Tu, S., and Reinberg, D. (2010). Molecular Signals of Epigenetic States. Science 330, 612–616. doi:10.1126/science.1191078
Boo, S. H., and Kim, Y. K. (2020). The Emerging Role of RNA Modifications in the Regulation of mRNA Stability. Exp. Mol. Med. 52, 400–408. doi:10.1038/s12276-020-0407-z
Bordin, D. L., Lirussi, L., and Nilsen, H. (2021). Cellular Response to Endogenous DNA Damage: DNA Base Modifications in Gene Expression Regulation. DNA Repair 99, 103051. doi:10.1016/j.dnarep.2021.103051
Buchmuller, B. C., Kosel, B., and Summerer, D. (2020). Complete Profiling of Methyl-CpG-Binding Domains for Combinations of Cytosine Modifications at CpG Dinucleotides Reveals Differential Read-Out in Normal and Rett-Associated States. Sci. Rep. 10, 4053. doi:10.1038/s41598-020-61030-1
Calwell, B. A., Liu, M. Y., Prasasya, R. D., Wang, T., DeNizio, J. E., Lee, N. A., et al. (2021). Functionally Distinct Roles for TET-Oxidized 5-methylcytosine Bases in Somatic Reprogramming to Pluripotency. Mol. Cell 81, 859–869. doi:10.1016/j.molcel.2020.11.045
Cervantes-Gracia, K., Gramalla-Schmitz, A., Weischledel, J., and Chahwan, R. (2021). APOBECS Orchestrate Genomic and Epigenomic Editing across Health and Disease. Trends Genet. 37, 1028–1043. doi:10.1016/j.tig.2021.07.003
Chellamuthu, A., and Gray, S. G. (2020). The RNA Methyltransferase NSUN2 and Its Potential Roles in Cancer. Cells 9, 1758. doi:10.3390/cells9081758
Chen, H., Shi, Z., Guo, J., Chang, K.-j., Chen, Q., Yao, C.-H., et al. (2020). The Human Mitochondrial 12S rRNA mC Methyltransferase METTL15 Is Required for Mitochondrial Function. J. Biol. Chem. 295, 8505–8513. doi:10.1074/jbc.ra119.12127
Chen, H., Yang, H., Zhu, X., Yadav, T., Ouyang, J., Truesdell, S. S., et al. (2020). m5C Modification of mRNA Serves a DNA Damage Code to Promote Homologous Recombination. Nat. Commun. 11, 2834. doi:10.1038/s41467-020-16722-7

Full#supplementary-material
Chen, X., Li, A., Sun, B.-F., Yang, Y., Han, Y.-N., Yuan, X., et al. (2019). 5-methylcytosine Promotes Pathogenesis of Bladder Cancer through Stabilizing mRNAs. Nat. Cell Biol. 21, 978–990. doi:10.1038/s41555-019-0361-y

Chen, Y. S., Yang, W. L., Zhao, Y. L., and Yang, Y. G. (2021). Dynamic Transcriptomic 3fC and its Regulatory Role in RNA Processing. Wiley Interdiscip. Rev. RNA. 12, e1639. doi:10.1002/wrna.1639

Chen, Z., Zhong, X., Xia, M., and Zhong, J. (2021). The Roles and Mechanisms of the m6A Reader Protein YTHDF1 in Tumor Biology and Human Diseases. Mol. Ther. - Nucleic Acids 26, 1270–1279. doi:10.1016/j.omtn.2021.10.023

Cheng, J. X., Chen, L. Y., Cloe, A., Yue, M., Wei, J., et al. (2018). RNA Cytosine Methylation and Methyltransferases Mediate Chromatin Organization and 5-azacytidine Response and Resistance in Leukaemia. Nat. Commun. 9, 1163. doi:10.1038/s41467-018-03513-4

Choi, I., Kim, R., Lim, H.-W., Kaestner, K. H., and Won, K.-J. (2014). 5-hydroxymethylcytosine Represses the Activity of Enhancers in Embryonic Stem Cells: A New Epigenetic Signature for Gene Regulation. BMC Genomics 15, 670. doi:10.1186/1471-2164-15-670

Cimmino, L., Abdel-Wahab, O., Levine, R. L., and Atlasi, I. (2011). TET Family Proteins and Their Role in Stem Cell Differentiation and Transformation. Cell Stem Cell 9, 193–204. doi:10.1016/j.stem.2011.08.007

Cui, X.-L., Nie, J., Ku, J., Doughty, U., West-Szymanski, D. C., Collin, F., et al. (2019). 5-methylcytosine Response and Resistance in Leukaemia. Nat. Commun. 10, 3161. doi:10.1038/s41467-020-19200-w

Dai, Z., Ramesh, V., and Locasale, J. W. (2020). The Evolving Metabolic Landscape of Chromatin Biology and Epigenetics. Nat. Rev. Genet. 21, 737–753. doi:10.1038/s41576-020-0270-8

Dawlaty, M. M., Breiling, A., Le, T., Barrass, M. I., Raddatz, G., Gao, Q., et al. (2014). Loss of Tet Enzymes Compromises Proper Differentiation of Embryonic Stem Cells. Dev. Cell 29, 102–111. doi:10.1016/j.devcel.2014.03.003

Deem, A. K., Li, X., and Tyler, J. K. (2012). Epigenetic Regulation of Genomic Integrity. Chromosoma 121, 131–151. doi:10.1007/s00412-011-0358-1

Delatte, B., Wang, F., Ngoc, L. Y., Collignon, E., Bonvin, E., Deplus, R., et al. (2016). Transcriptome-wide Distribution and Function of RNA Hydroxymethylcytosine. Science 351, 282–285. doi:10.1126/science.aac5253

DeNizio, J. E., Liu, M. Y., Leddin, E. M., Cisneros, G. A., and Kohli, R. M. (2019). Selectivity and Promiscuity in TET-Mediated Oxidation of 5-Methylcytosine in DNA and RNA. Biochemistry 58, 411–421. doi:10.1021/acs.biochem.8b00912

Du, Q., Lue, P.-L., Stitzaker, C., and Clark, S. J. (2015). Methyl-CpG-binding Domain Proteins: Readers of the Epigenome. Epigenomics 7, 1051–1073. doi:10.2217/epi.15.39

Enroth, C., Poulsen, L. D., Iversen, S., Kirpekar, F., Albrechtsen, A., and Vinther, J. (2016). Epigenetic Landscape of the Human Genome and Disease. Nat. Struct. Mol. Biol. 23, 62–70. doi:10.1038/nsmb.3094-020-05526-w

He, L., Li, H., Wu, A., Peng, Y., Shu, G., and Yin, G. (2019). Functions of N6-Methyladenosine and its Role in Cancer. Mol. Cancer 18, 176. doi:10.1186/s12943-019-1109-9

He, Y.-F., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., et al. (2011). Tet-mediated 5-hydroxymethylcytosine Landscape of the Human Genome. Science 333, 1303–1307. doi:10.1126/science.1210944

He, Y., Shi, Q., Zhang, Y., Yuan, X., and Yu, Z. (2020). Transcription-Wide 5-Methylcytosine Functional Profiling of Long Non-Coding RNA in Hepatocellular Carcinoma. Oncol. Lett. 20, 6877–6885. doi:10.3892/ol.2020.12652

Hsu, P. J., Shi, H., and He, C. (2017). Epitranscriptomic Influences on Development and Disease. Genome Biol. 18, 197. doi:10.1186/s13059-017-1336-6

Hu, C., Liu, X., Zeng, Y., Liu, J., and Wu, F. (2021). DNA Methyltransferase Inhibitors Combination Therapy for the Treatment of Solid Tumor: Mechanism and Clinical Application. Clin. Epigenet. 13, 166. doi:10.1186/s13148-021-01154-x

Hu, Y., Chen, C., Tong, X., Chen, S., Hu, X., Pan, B., et al. (2021). NSUN2 Modified by SUMO-2/3 Promotes Gastric Cancer Progression and Regulates mRNA m5C Methylation. Cell Death Dis. 12, 842. doi:10.1038/s41419-021-04127-3

Huang, T., Chen, W., Liu, J., Gu, N., and Zhang, R. (2019). Genome-wide Identification of mRNA 5-methylcytosine in Mammals. Nat. Struct. Mol. Biol. 26, 380–388. doi:10.1038/s41594-019-0128-x

Huang, W., Kong, F., Li, R., Chen, X., and Wang, K. (2022). Emerging Roles of m6A RNA Methyltransferases Regulators in Gynecological Cancer. Front. Oncol. 12, 827956. doi:10.3389/fonc.2022.827956

Huang, Z.-X., Li, J., Xiong, Q.-P., Li, H., Wang, E.-D., and Liu, R.-J. (2021). Position 34 of tRNA Is a Discriminative Element for m5C38 Modification by Human DNMT2. Nucleic Acids Res. 49, 13045–13061. doi:10.1093/nar/gkaa1148

Huang, Z., Pan, J., Wang, H., Du, X., Xu, Y., and Zhang, Z. (2021). Prognostic Significance and Tumor Immune Microenvironment Heterogeneity of m5C RNA Methylation Regulators in Triple-Negative Breast Cancer. Front. Cell Dev. Biol. 9, 657547. doi:10.3389/fcell.2021.657547

Ibrahim, J., Op de Beeck, K., Fransen, E., Peeters, M., and Van Camp, G. (2022). Genome-wide DNA Methylation Profiling and Identification of Potential Pan-
Xie, S., Chen, W., Chen, K., Chang, Y., Yang, F., Lin, A., et al. (2020). Emerging Roles of RNA Methylation in Gastrointestinal Cancer. Cancer Cell Int. 20, 585. doi:10.1186/s12935-020-01679-w
Xiong, X., Li, X., and Yi, C. (2018). N1-methyladenosine Methylose in Messenger RNA and Non-coding RNA. Curr. Opin. Chem. Biol. 45, 179–186. doi:10.1016/j.copcb.2018.06.017
Xu, B., Wang, H., and Tan, L. (2021). Dysregulated TET Family Genes and Ablative Smc Oxidation in Breast Cancer: Causes and Consequences. Cancers (Basel) 13, 6039. doi:10.3390/cancers13236039
Xu, G.-L., and Bochtler, M. (2020). Reversal of Nucleobase Methylation by DNAzymes. Nat. Chem. Biol. 16, 1160–1169. doi:10.1038/s41588-020-00675-5
Xu, Q., Wang, C., Zhou, J. X., Xu, Z. M., Gao, J., Sui, P., et al. (2022). Loss of TET Reprogramms Wnt Signaling through Impaired Demethylation to Promote Lung Cancer Development. Proc. Natl. Acad. Sci. U. S. A. 119, e210799119. doi:10.1073/pnas.2107991119
Xue, C., Zhao, Y., and Li, L. (2020). Advances in RNA Cytosine-5 Methylation: Detection, Regulatory Mechanisms, Biological Functions and Links to Cancer. Biomark. Res. 8, 43. doi:10.1186/s40364-020-00225-0
Xue, M., Shi, Q., Zheng, L., Li, Q., Yang, L., and Zhang, Y. (2020). Gene Signatures of m5C Regulators May Predict Prognoses of Patients with Head and Neck Squamous Cell Carcinoma. Am. J. Transl. Res. 12, 6841–6852.
Yang, H., Wang, Y., Xiang, Y., Yadav, T., Ouyang, J., Phoon, L., et al. (2022). FMRP Promotes Transcription-Coupled Homologous Recombination via Facilitating TET1-Mediated m5C RNA Modification Demethylation. Proc. Natl. Acad. Sci. U. S. A. 119, e2116251119. doi:10.1073/pnas.2116251119
Yang, J., Bashkeneva, N., Zhang, R., Huang, X., and Wang, J. (2020). The Roles of TET Family Proteins in Development and Stem Cells. Development 147, dev183129. doi:10.1242/dev.183129
Yang, X., Liu, Q.-L., Xu, W., Zhang, Y.-C., Yang, Y., Ju, L.-F., et al. (2019). m6A Promotes R-Loop Formation to Facilitate Transcription termination. A Promotes R-Loop Formation to Facilitate Transcription Termination. Cell Res. 29, 1035–1038. doi:10.1038/s41422-019-0235-7
Yi, J., Gao, R., Chen, Y., Yang, Z., Han, P., Zhang, H., et al. (2017). Overexpression of NSUN2 by DNA Hypomethylation Is Associated with Metastatic Progression in Human Breast Cancer. Oncotarget 8, 20751–20765. doi:10.18632/oncotarget.10612
Yuan, F., Bi, Y., Siejka-Zielinska, P., Zhou, Y.-L., Zhang, X.-X., and Song, C.-X. (2019). Bisulfite-free and Base-Resolution Analysis of 5-methylcytidine and 5-hydroxymethylcytidine in RNA with Peroxotungstate. Chem. Commun. 55, 2328–2331. doi:10.1039/c9cc00274j
Yue, X., and Rao, A. (2020). TET Family DNAzymes and the TET Activator Vitamin C in Immune Responses and Cancer. Blood 136, 1394–1401. doi:10.1182/blood.2019041158
Zeng, Y., Wang, S., Gao, S., Soares, F., Ahmed, M., Guo, H., et al. (2018). Refined RIP-Seq Protocol for Epitranscriptome Analysis with Low Input Materials. PLoS Biol. 16, e2006092. doi:10.1371/journal.pbio.2006092
Zhang, C., Chen, L., Peng, D., Jiang, A., He, Y., Zeng, Y., et al. (2020). METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DDSs by Modulating DNA-RNA Hybrid Accumulation. Mol. Cell 79, 425–442. doi:10.1016/j.molcel.2020.06.017
Zhang, M., Zhai, Y., Zhang, S., Dai, X., and Li, Z. (2020). Roles of N6-Methyladenosine (m6A) in Stem Cell Fate Decisions and Early Embryonic Development in Mammals. Front. Cell Dev. Biol. 8, 782. doi:10.3389/fcell.2020.00782
Zhang, Q., Liu, F., Chen, W., Miao, H., Liang, H., Liao, Z., et al. (2021). The Role of RNA m5C Modification in Cancer Metastasis. Int. J. Biol. Sci. 17, 3369–3380. doi:10.7150/ijbs.64139
Zhang, Q., Zheng, Q., Yu, X., He, Y., and Guo, W. (2020). Overview of Distinct 5-methylcytosine Profiles of Messenger RNA in Human Hepatocellular Carcinoma and Paired Adjacent Non-tumor Tissues. J. Transl. Med. 18, 245. doi:10.1186/s12967-020-02417-6
Zhang, X., Gan, Y., Zou, G., Guan, J., and Zhou, S. (2019). Genome-wide Analysis of Epigenetic Dynamics across Human Developmental Stages and Tissues. BMC Genomics 20, 221. doi:10.1186/s12864-019-5472-0
Zhao, L.-Y., Song, J., Liu, Y., Song, C.-X., and Yi, C. (2020). Mapping the Epigenetic Modifications of DNA and RNA. Protein Cell 11, 792–808. doi:10.13238/molcel.2019.07.005
Zhou, Z., Li, J., Yu, H., Han, J., Yang, X., Feng, D., et al. (2020). Mechanism of RNA Modification N6-Methyladenosine in Human Cancer. Mol. Cancer 19, 104. doi:10.1186/s12943-020-01216-3
Zhu, X., Wang, X., Yan, W., Yang, H., Xiang, Y., Lv, F., et al. (2021). A Polygenic Methylation Prediction Model Associated with Response to Chemotherapy in Epithelial ovarian Cancer. Mol. Ther. Oncolytics 20, 545–555. doi:10.1016/j.omt.2021.02.012
Zhou, K. I., Shi, H., Lyu, R., Wylder, A. C., Matuszek, Z., Pan, J. N., et al. (2019). Regulation of Co-transcriptional Pre-mRNA Splicing by m6A through the Low-Complexity Protein hnRNPG. Mol. Cell 76, 70–81. e9. doi:10.1016/j.molcel.2019.07.005
Zhuo, Z., Lv, J., Yu, H., Han, J., Yang, X., Feng, D., et al. (2020). Mechanism of RNA Modification N6-Methyladenosine in Human Cancer. Mol. Cancer 19, 104. doi:10.1186/s12943-020-01216-3
Zhu, X., Wang, X., Yan, W., Yang, H., Xiang, Y., Lv, F., et al. (2021). Ubiquitination-mediated Degradation of TRDMT1 Regulates Homologous Recombination and Therapeutic Response. Nat. Cancer 3, zcab010. doi:10.1038/s41593-021-00675-5
Zhu, Z.-M., Huo, F.-C., and Pei, D.-S. (2020). Function and Evolution of RNA N6-Methyladenosine Methylation Primarily Affects the ErbB and PI3K-Akt Signaling Pathways in Cancer Development. Epigenetics Chromatin 13, 60. doi:10.1186/s13072-020-00225-0
Zhu, Z.-M., Huo, F.-C., and Pei, D.-S. (2020). Function and Evolution of RNA N6-Methyladenosine Methylation Primarily Affects the ErbB and PI3K-Akt Signaling Pathways in Cancer Development. Epigenetics Chromatin 13, 60. doi:10.1186/s13072-020-00225-0
